Management of multiple myeloma: the impact of ixazomib's approval in Canada.

Donna E Reece speaks to Laura Dormer, Commissioning Editor: Dr Donna E Reece is a Professor of Medicine and Director of the Program for Multiple Myeloma and Related Diseases in the Department of Medical Oncology and Hematology at Princess Margaret Hospital/University of Toronto. She earned a Bachelor of Arts degree at the University of Texas, Austin, and graduated as valedictorian with a medical degree from Baylor College of Medicine, Houston, Texas. She completed an internship in Internal Medicine at the University of Colorado Affiliated Hospitals, a residency and Chief Residency in Internal Medicine at Jewish Hospital, St Louis, and a Fellowship in Hematology/Oncology at Barnes Hospital, Washington University, St Louis, Missouri. She was a fellow and later a leukemia/stem cell transplant staff physician at Vancouver General Hospital/University of British Columbia for over 10 years. She then served as Director of the Outpatient Leukemia/Stem Cell Transplant Program, and later interim director, of the Blood and Marrow Transplant Program of the Markey Cancer Center at the University of Kentucky, Lexington, Kentucky until her appointment to Princess Margaret Hospital in Toronto in 2001. Dr Reece received the David and Molly Bloom Chair in Myeloma Research in 2009. She is currently the co-chair of the Multiple Myeloma Clinical Trials Group of the National Cancer Institute of Canada, member of the Scientific Advisory Board of the International Myeloma Foundation, and member of the Project Review Committee of the MMRC (Multiple Myeloma Research Consortium). She is also the Chief Medical Officer of the Myeloma Canada Research Network and serves on the board of directors of Myeloma Canada. Her career focus has been in the areas of hematopoietic stem cell transplantation, lymphoid malignancies and plasma cell dyscrasias. She has published numerous articles in these areas.